Autolus Therapeutics plc, a UK-based clinical-stage biopharmaceutical company, is changing the game in cancer treatment. The company is currently developing T cell therapies that are designed to target and eradicate cancer cells. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that's currently in Phase 1b/2 clinical trials for the treatment of adult acute lymphoblastic leukemia (ALL). Additionally, Autolus is developing AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL. The company is also working on AUTO4, a programmed T cell investigational therapy that targets TRBC1 and TRBC2 for the treatment of peripheral T-cell lymphoma. Furthermore, they are developing AUTO6NG, a programmed T cell investigational therapy that targets GD2, which is currently in preclinical trials for the treatment of neuroblastoma. Lastly, the company's product candidate AUTO8 is in a Phase I clinical trial for multiple myeloma. Autolus is also working on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was founded in 2014 and is currently headquartered in London, UK.
Autolus Therapeutics plc's ticker is AUTL
The company's shares trade on the NASDAQ stock exchange
They are based in London, England
There are 201-500 employees working at Autolus Therapeutics plc
It is https://www.autolus.com/
Autolus Therapeutics plc is in the Healthcare sector
Autolus Therapeutics plc is in the Biotechnology industry
The following five companies are Autolus Therapeutics plc's industry peers: